Iovance Biotherapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Tuesday, February 28, 2023
21 févr. 2023 16h01 HE
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will...
Iovance Biotherapeutics Provides Corporate, Clinical, and Regulatory Updates
23 janv. 2023 08h00 HE
|
Iovance Biotherapeutics, Inc.
Acquisition of Worldwide Rights to Proleukin® Provides Immediate and Ongoing Revenue and Secures IL-2 Supply for Clinical and Future Commercial TIL Therapy Positive FDA Feedback on Phase 3...
Iovance Biotherapeutics to Present at Upcoming Conferences
30 nov. 2022 07h00 HE
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today...
Iovance Biotherapeutics Provides Update on Biologics License Application Submission for Lifileucel in Advanced Melanoma
18 nov. 2022 06h30 HE
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., Nov. 18, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) today announced that its ongoing rolling Biologics License Application (BLA) submission to the U.S....
Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting
10 nov. 2022 12h33 HE
|
Iovance Biotherapeutics, Inc.
31% Objective Response Rate (ORR) and Median Duration of Response (mDOR) Not Reached at 36.5 Months Median Study Follow Up in C-144-01 Trial (Cohorts 2 and 4) 42% of Responses Lasted for 24+ Months ...
Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting
07 nov. 2022 08h01 HE
|
Iovance Biotherapeutics, Inc.
Clinically Meaningful and Durable Activity in Largest Cell Therapy Clinical Trial in Patients with Melanoma After Progression on Immune Checkpoint Inhibitors 31% Objective Response Rate (ORR) and...
Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2022 Financial Results and Corporate Updates
03 nov. 2022 16h01 HE
|
Iovance Biotherapeutics, Inc.
First Biologics License Application (BLA) Submission Initiated and on Track to Complete in 4Q22 SAN CARLOS, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA),...
Iovance Biotherapeutics to Host Third Quarter Financial Results Conference Call and Webcast on Thursday, November 3, 2022
24 oct. 2022 16h01 HE
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will...
Iovance Biotherapeutics Announces First Patient Dosed with PD-1 Inactivated Tumor Infiltrating Lymphocyte (TIL) Therapy
10 oct. 2022 07h30 HE
|
Iovance Biotherapeutics, Inc.
First Genetically Modified (TALEN®-edited) Iovance TIL Therapy with Inactivated PD-1 Expression SAN CARLOS, Calif., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA),...
Iovance Biotherapeutics to Present Clinical Data for Lifileucel Tumor Infiltrating Lymphocyte (TIL) Therapy in Advanced Melanoma at Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
05 oct. 2022 08h05 HE
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today...